Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 1984 Feb;63(2):139-42.

Effects of butorphanol, nalbuphine, and fentanyl on intrabiliary tract dynamics

  • PMID: 6691579

Effects of butorphanol, nalbuphine, and fentanyl on intrabiliary tract dynamics

R L McCammon et al. Anesth Analg. 1984 Feb.

Abstract

The effects of equianalgesic doses of fentanyl citrate (100 micrograms; n = 20), butorphanol tartrate (2 mg; n = 20), and nalbuphine hydrochloride (10 mg; n = 16) on biliary tract dynamics were examined in patients anesthetized with enflurane-nitrous oxide. After removal of the gall bladder, the common bile duct or cystic duct remnant was cannulated with an 18-gauge catheter. Using a modified Caroli apparatus, control measurements of flow through the common bile duct into the duodenum over 60 sec and resting intrabiliary tract pressure were obtained. Patients then were given one of the drugs intravenously and measurements were repeated 5 min later. Flow rates decreased 35%, 21%, and 13% after fentanyl, butorphanol, and nalbuphine, respectively. Similarly, resting intrabiliary tract pressures increased by 23%, 12%, and 6%, respectively. All changes were statistically significant (P less than 0.05) except for the increase in intrabiliary tract pressure after nalbuphine. Likewise, the incidence of decreases in flow rate or increases in intrabiliary tract pressure more than 20% was greater after fentanyl than after either butorphanol or nalbuphine. Agonist-antagonist analgesics may be advantageous in patients with known or suspected biliary tract disease.

PubMed Disclaimer

LinkOut - more resources